• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Rockwell Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/20/25 4:13:55 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    false 0001041024 0001041024 2025-05-20 2025-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

     

     

    Date of Report (Date of earliest event reported): May 20, 2025

     

    Rockwell Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 000-23661 38-3317208
    (State or other jurisdiction
    of incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)

     

    30142 S. Wixom Road, Wixom, Michigan 48393

    (Address of principal executive offices, including zip code)

     

    (248) 960-9009

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class  Trading  Symbol  Name of Each exchange on which
    registered
    Common Stock, par value $0.0001  RMTI  Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.07         Submission of Matters to a Vote of Security Holders.

     

    On May 20, 2025, Rockwell Medical, Inc. (the “Company”) held its 2025 Annual Meeting of the Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:

     

    Proposal One: To elect the two Class I directors to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his successor has been duly elected and qualified.

     

       For   Against   Abstain   Broker Non-Votes 
    John G. Cooper   14,278,753    615,440    36,816    8,372,386 
    Allen Nissenson, MD   14,396,057    500,966    33,986    8,372,386 
                         
    Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers.
     
    For  Against    Abstain    Broker Non-Votes     
    13,310,315   1,066,331    554,363    8,372,386     
                         
    Proposal Three: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2025.
                         
    For  Against   Abstain                 
    21,767,571   361,807    1,174,017                 
                               
    Proposal Four: To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to, among other things, increase the number of shares reserved for issuance thereunder by 5,000,000 shares.
                               
    For  Against    Abstain    Broker Non-Votes     
    12,862,271   2,013,968    54,770    8,372,386         

      

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ROCKWELL MEDICAL, INC.
         
    Date: May 20, 2025 By:  /s/ Mark Strobeck
        Mark Strobeck
        Chief Executive Officer

     

     

     

    Get the next $RMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lau Joan was granted 50,000 shares, increasing direct ownership by 79% to 113,111 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:10:30 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cooper John G was granted 50,000 shares, increasing direct ownership by 52% to 145,451 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:08:46 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nissenson Allen was granted 50,000 shares, increasing direct ownership by 54% to 142,597 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:07:20 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care